{"analyses":[{"ciLowerLimit":"0.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.87","estimateComment":"The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0684","paramType":"Odds Ratio (OR)","paramValue":"1.35","statisticalComment":"Adjusted for geographic region and ECOG score.","statisticalMethod":"Stratified exact test"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","estimateComment":"The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.9822","paramType":"Odds Ratio (OR)","paramValue":"0.98","statisticalComment":"Adjusted for geographic region and ECOG score","statisticalMethod":"Stratified exact test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.55","upperLimit":"60.77","value":"55.21"},{"groupId":"OG001","lowerLimit":"42.12","upperLimit":"53.28","value":"47.68"},{"groupId":"OG002","lowerLimit":"32.95","upperLimit":"46.41","value":"39.53"},{"groupId":"OG003","lowerLimit":"33.61","upperLimit":"47.24","value":"40.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"323"},{"groupId":"OG002","value":"215"},{"groupId":"OG003","value":"211"}],"units":"Participants"}],"description":"Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Wild-type KRAS - FOLFOX + Panitumumab"},{"description":"Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG001","title":"Wild-type KRAS - FOLFOX"},{"description":"Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Mutant KRAS - FOLFOX + Panitumumab"},{"description":"Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG003","title":"Mutant KRAS - FOLFOX"}],"paramType":"NUMBER","populationDescription":"KRAS Evaluable Central Tumor Response Analysis Set (subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review).","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.","title":"Percentage of Participants With an Objective Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}